These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 33852862)

  • 21. Structural and Functional Characterization of a Cross-Reactive Dengue Virus Neutralizing Antibody that Recognizes a Cryptic Epitope.
    Li J; Watterson D; Chang CW; Che XY; Li XQ; Ericsson DJ; Qiu LW; Cai JP; Chen J; Fry SR; Cheung STM; Cooper MA; Young PR; Kobe B
    Structure; 2018 Jan; 26(1):51-59.e4. PubMed ID: 29249606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors.
    Kuzmina NA; Younan P; Gilchuk P; Santos RI; Flyak AI; Ilinykh PA; Huang K; Lubaki NM; Ramanathan P; Crowe JE; Bukreyev A
    Cell Rep; 2018 Aug; 24(7):1802-1815.e5. PubMed ID: 30110637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Role of Conserved N-Linked Glycans on Ebola Virus Glycoprotein 2.
    Lennemann NJ; Walkner M; Berkebile AR; Patel N; Maury W
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S204-9. PubMed ID: 26038399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural basis for differential neutralization of ebolaviruses.
    Bale S; Dias JM; Fusco ML; Hashiguchi T; Wong AC; Liu T; Keuhne AI; Li S; Woods VL; Chandran K; Dye JM; Saphire EO
    Viruses; 2012 Apr; 4(4):447-70. PubMed ID: 22590681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural basis for Marburg virus neutralization by a cross-reactive human antibody.
    Hashiguchi T; Fusco ML; Bornholdt ZA; Lee JE; Flyak AI; Matsuoka R; Kohda D; Yanagi Y; Hammel M; Crowe JE; Saphire EO
    Cell; 2015 Feb; 160(5):904-912. PubMed ID: 25723165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mapping of Ebolavirus Neutralization by Monoclonal Antibodies in the ZMapp Cocktail Using Cryo-Electron Tomography and Studies of Cellular Entry.
    Tran EE; Nelson EA; Bonagiri P; Simmons JA; Shoemaker CJ; Schmaljohn CS; Kobinger GP; Zeitlin L; Subramaniam S; White JM
    J Virol; 2016 Sep; 90(17):7618-27. PubMed ID: 27279622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanism of human antibody-mediated neutralization of Marburg virus.
    Flyak AI; Ilinykh PA; Murin CD; Garron T; Shen X; Fusco ML; Hashiguchi T; Bornholdt ZA; Slaughter JC; Sapparapu G; Klages C; Ksiazek TG; Ward AB; Saphire EO; Bukreyev A; Crowe JE
    Cell; 2015 Feb; 160(5):893-903. PubMed ID: 25723164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses.
    Clark LE; Mahmutovic S; Raymond DD; Dilanyan T; Koma T; Manning JT; Shankar S; Levis SC; Briggiler AM; Enria DA; Wucherpfennig KW; Paessler S; Abraham J
    Nat Commun; 2018 May; 9(1):1884. PubMed ID: 29760382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.
    Keck ZY; Enterlein SG; Howell KA; Vu H; Shulenin S; Warfield KL; Froude JW; Araghi N; Douglas R; Biggins J; Lear-Rooney CM; Wirchnianski AS; Lau P; Wang Y; Herbert AS; Dye JM; Glass PJ; Holtsberg FW; Foung SK; Aman MJ
    J Virol; 2016 Jan; 90(1):279-91. PubMed ID: 26468532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody Repertoires to the Same Ebola Vaccine Antigen Are Differentially Affected by Vaccine Vectors.
    Meyer M; Yoshida A; Ramanathan P; Saphire EO; Collins PL; Crowe JE; Samal S; Bukreyev A
    Cell Rep; 2018 Aug; 24(7):1816-1829. PubMed ID: 30110638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.
    Holtsberg FW; Shulenin S; Vu H; Howell KA; Patel SJ; Gunn B; Karim M; Lai JR; Frei JC; Nyakatura EK; Zeitlin L; Douglas R; Fusco ML; Froude JW; Saphire EO; Herbert AS; Wirchnianski AS; Lear-Rooney CM; Alter G; Dye JM; Glass PJ; Warfield KL; Aman MJ
    J Virol; 2016 Jan; 90(1):266-78. PubMed ID: 26468533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Achieving cross-reactivity with pan-ebolavirus antibodies.
    King LB; Milligan JC; West BR; Schendel SL; Ollmann Saphire E
    Curr Opin Virol; 2019 Feb; 34():140-148. PubMed ID: 30884329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody.
    Li Y; Pierce BG; Wang Q; Keck ZY; Fuerst TR; Foung SK; Mariuzza RA
    J Biol Chem; 2015 Apr; 290(16):10117-25. PubMed ID: 25737449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site.
    Howell KA; Qiu X; Brannan JM; Bryan C; Davidson E; Holtsberg FW; Wec AZ; Shulenin S; Biggins JE; Douglas R; Enterlein SG; Turner HL; Pallesen J; Murin CD; He S; Kroeker A; Vu H; Herbert AS; Fusco ML; Nyakatura EK; Lai JR; Keck ZY; Foung SKH; Saphire EO; Zeitlin L; Ward AB; Chandran K; Doranz BJ; Kobinger GP; Dye JM; Aman MJ
    Cell Rep; 2016 May; 15(7):1514-1526. PubMed ID: 27160900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection.
    Flyak AI; Shen X; Murin CD; Turner HL; David JA; Fusco ML; Lampley R; Kose N; Ilinykh PA; Kuzmina N; Branchizio A; King H; Brown L; Bryan C; Davidson E; Doranz BJ; Slaughter JC; Sapparapu G; Klages C; Ksiazek TG; Saphire EO; Ward AB; Bukreyev A; Crowe JE
    Cell; 2016 Jan; 164(3):392-405. PubMed ID: 26806128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structures of Ebola virus GP and sGP in complex with therapeutic antibodies.
    Pallesen J; Murin CD; de Val N; Cottrell CA; Hastie KM; Turner HL; Fusco ML; Flyak AI; Zeitlin L; Crowe JE; Andersen KG; Saphire EO; Ward AB
    Nat Microbiol; 2016 Aug; 1(9):16128. PubMed ID: 27562261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The use of monoclonal antibodies for the treatment of Ebola virus disease.].
    Sizikova TE; Borisevich GV; Shcheblyakov DV; Burmistrova DA; Lebedev VN
    Vopr Virusol; 2018; 63(6):245-249. PubMed ID: 30641019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure of an antibody in complex with its mucin domain linear epitope that is protective against Ebola virus.
    Olal D; Kuehne AI; Bale S; Halfmann P; Hashiguchi T; Fusco ML; Lee JE; King LB; Kawaoka Y; Dye JM; Saphire EO
    J Virol; 2012 Mar; 86(5):2809-16. PubMed ID: 22171276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cell Fusion Induced by a Fusion-Active Form of Human Cytomegalovirus Glycoprotein B (gB) Is Inhibited by Antibodies Directed at Antigenic Domain 5 in the Ectodomain of gB.
    Reuter N; Kropff B; Schneiderbanger JK; Alt M; Krawczyk A; Sinzger C; Winkler TH; Britt WJ; Mach M; Thomas M
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32641474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of an antibody for pan-ebolavirus therapy.
    Furuyama W; Marzi A; Nanbo A; Haddock E; Maruyama J; Miyamoto H; Igarashi M; Yoshida R; Noyori O; Feldmann H; Takada A
    Sci Rep; 2016 Feb; 6():20514. PubMed ID: 26861827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.